Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 1.00 |
| ▸ | ANPEP | P15144 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | RAB9A | P51151 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL13170049 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL12799451 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305897-B | Three-gene report system and establishment method and application thereof | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 2023-03-31 | — | — | CN | claimed |
| CN-118207258-A | Sensitive cell line for detecting transduction titer of adeno-associated virus, construction method and application thereof | 浙江恒驭生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116445317-A | New streptomyces albus strain for producing puromycin and application thereof | 杭州职业技术学院 | 2023-07-18 | — | — | CN | disclosed |
| CN-110283848-B | Application of magnetoinductive protein as magnetic resonance imaging tracer in stem cell tracing | 东南大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-114908055-A | Stem cell for over-expressing Magr to regulate iron homeostasis in vivo and preparation method thereof | 东南大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-113308470-A | sgRNA of targeted ARID1A gene knockout, method for constructing ARID1A gene deletion cell strain and application | 西安交通大学医学院第一附属医院 | 2021-08-27 | — | — | CN | disclosed |
| CN-113226336-A | Method for delivering gene in cell | 苏州克睿基因生物科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-107868785-B | Inhibitor for targeted therapy of lung cancer and application thereof, and application of RUVBL1 gene as drug target in screening anti-lung cancer drugs | 昆明理工大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-3377896-A1 | HIGH-THROUGHPUT IMAGING-BASED METHODS FOR PREDICTING CELL-TYPE-SPECIFIC TOXICITY OF XENOBIOTICS WITH DIVERSE CHEMICAL STRUCTURES | Agency For Science, Technology And Research (SG) | 2018-09-26 | — | — | EP | disclosed |
| EP-3289092-A1 | METHODS OF MANUFACTURING THERAPEUTIC PROTEINS | Momenta Pharmaceuticals, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017091147-A1 | HIGH-THROUGHPUT IMAGING-BASED METHODS FOR PREDICTING CELL-TYPE-SPECIFIC TOXICITY OF XENOBIOTICS WITH DIVERSE CHEMICAL STRUCTURES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016176275-A1 | METHODS OF MANUFACTURING THERAPEUTIC PROTEINS | MOMENTA PHARMACEUTICALS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |